Lack of Association Between the CYP1A1 Ile462Val Polymorphism and Endometrial Cancer Risk: a Meta-analysis

  • Wang, Xi-Wen ;
  • Zhong, Tian-Yu ;
  • Xiong, Yun-Hui ;
  • Lin, Hai-Bo ;
  • Liu, Qing-Yi
  • Published : 2012.08.31


Purpose: Any association between the CYP1A1 Ile462Val polymorphism and endometrial cancer risk remains inconclusive. For a more precise estimate, we performed the present meta-analysis. Methods: PUBMED, OVID and EMBASE were searched for the studies which met inclusion criteria. Data in all eligible studies were evaluated and extracted by two authors independently. The meta-analysis estimated pooled odds ratio (OR) with 95% confidence interval (CI) for endometrial cancer risk attributable to the CYP1A1 Ile462Val polymorphism. Results: A total of 7 studies were included in this meta-analysis. The results indicated no association between endometrial cancer risk and the CYP1A1 Ile462Val polymorphism (for Val vs Ile allele model [OR 1.09, 95% CI 0.73-1.62]; for Val.Val vs Ile.Ile genotype model [OR 1.54, 95% CI 0.56-4.23]; for (Ile.Val + Val.Val) vs Ile.Ile genotpye model [OR 1.08, 95% CI 0.71-1.63]; for Val.Val vs (Ile.Ile + Ile.Val) genotype model [OR 1.46, 95% CI 0.53-4.04]). Conclusions: This meta-analysis suggests that there is no association between endometrial cancer risk and the CYP1A1 Ile462Val polymorphism.


CYP1A1;endometrial cancer;polymorphism;meta-analysis


  1. Ashton KA, Proietto A, Otton G, et al (2010). Polymorphisms in genes of the steroid hormone biosynthesis and metabolism pathways and endometrial cancer risk. Cancer Epidemiol, 34, 328-37.
  2. Auersperg N, Edeson MI, Mok SC, et al (1998) The biology of ovarian cancer. Semin Oncol, 25, 281-304.
  3. Barrena Medel NI, Bansal S, Miller DS, et al (2009). Pharmacotherapy of endometrial cancer. Expert Opin Pharmacother, 10, 1939-51.
  4. Cochran WG (1954). The combination of estimates from different experiments. Biometrics, 10, 101-29.
  5. Cosma G, Crofts F, Taioli E, et al (1993). Relationship between genotype and function of the human CYP1A1 gene. J Toxicol Environ Health, 40, 309-16.
  6. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
  7. Doherty JA, Weiss NS, Freeman RJ, et al (2005). Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer.. Cancer Epidemiol Biomarkers Prev, 14, 357-66.
  8. Drakoulis N, Cascorbi I, Brockmoller J, et al (1994) Polymorphism in the human CYP 1 A 1gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3'- flanking region. Clin Invest, 72, 240-8.
  9. Egger M, Davey Smith G. Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.
  10. Elwood JM, Cole P, Rothman KJ, et al (1977). Epidemiology of endometrial cancer. J Natl Cancer Inst, 59, 1055-60.
  11. Esinler I, Aktasy D, Alikasifogluy M, et al (2006). CYP1A1 gene polymorphism and risk of endometrial hyperplasia and endometrial carcinoma. Int J Gynecol Cancer, 16, 1407-11.
  12. Esteller M, Garcia A, Martinez-Palones JM, et al (1997). Germ line polymorphisms in cytochrome-P450 1A1 (C4887 CYP1A1) and methylenetetrahydrofolate reductase (MTHFR) genes and endometrial cancer susceptibility. Carcinogenesis, 18, 2307-11.
  13. Esteller M, Garcia A, Martinez-Palones JM, et al (1997). Susceptibility to endometrial cancer: influence of allelism at p53, glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYP1A1) loci. Br J Cancer, 75, 1385-8.
  14. Fader AN, Arriba LN, Frasure HE, et al (2009). Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol, 114, 121-7
  15. Hayashi S, Watanabe J, Nakachi K, et al (1991). Genetic linkage of lung cancer-associated Msp1 polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P4501A1. J Biochem, 110, 407-11.
  16. Herrington CS (2001). What we could do now: molecular pathology of gynaecological cancer. Mol Pathol, 54, 222-4.
  17. Higgins JP, Thompson SE (2002). Quantifying heterogeneity in a metaanalysis. Stat Med, 21, 1539-58.
  18. Hirata H, Hinoda Y, Okayama N, et al (2008). CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility. Cancer, 112, 1964-73.
  19. Kawajiri K, Nakachi K, Imai K, et al (1993). The CYP1A1 gene and cancer susceptibility. Crit Rev Oncol Hematol, 14, 77-7.
  20. Key TJ, Pike MC (1988). The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer, 57, 205-12.
  21. Kiyohara C, Hirohata T, Inutsuka S (1996). The relationship between aryl hydrocarbon hydroxylase and polymorphisms of the CYP1A1 gene. Jpn J Cancer Res, 87, 18-24.
  22. La Vecchia C, Decarli A, Fasoli M, et al (1986). Nutrition and diet in the etiology of endometrial cancer. Cancer, 57, 1248-53.<1248::AID-CNCR2820570631>3.0.CO;2-V
  23. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  24. Martucci CP, Fishman J (1993). P450 enzymes of estrogen metabolism. Pharmacol Ther, 57, 237-57.
  25. McGrath M, Hankinson SE, De Vivo I (2007). Cytochrome P450 1A1, cigarette smoking, and risk of endometrial cancer (United States). Cancer Causes Control, 18, 1123-30.
  26. Petersen DD, McKinney CE, Ikeya K, et al (1991). Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP. Am J Hum Genet, 48, 720-5.
  27. Rebbeck TR, Troxel AB, Wang Y, et al (2006). Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk. J Natl Cancer Inst, 98, 1311-20.
  28. Schwarz D, Kisselev P, Schunck WH, et al (2000). Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics, 10, 519-30.
  29. Seremak-Mrozikiewicz A, Drews K, Semczuk A, et al (2005). CYP1A1 alleles in female genital cancers in the Polish population. Eur J Obstet Gynecol Reprod Biol, 118, 246-50.
  30. Sugawara T, Nomura E, Sagawa T, et al (2003). CYP1A1 polymorphism and risk of gynecological malignancy in Japan. Int J Gynecol Cancer, 13, 785-90.
  31. Taioli E, Crofts F, Trachman J, et al (1995) Radical differences in CYP1A1 genotype and function. Toxicol Lett, 77, 357-62.
  32. Zhang ZY, Fasco MJ, Huang L, et al (1996). Characterization of purified human recombinant cytochrome P4501A1-Ile462 and -Val462: assessment of a role for the rare allele in carcinogenesis. Cancer Res, 56, 3926-33.
  33. Zintzaras E, Chatzoulis DZ, Karabatsas CH, et al (2005). The relationship between C677T methylenetetrahydrofolate reductase gene polymorphism and retinopathy in type 2 diabetes: a metaanalysis. J Hum Genet, 50, 267-75.

Cited by

  1. Meta-analysis of Association Studies of CYP1A1 Genetic Polymorphisms with Digestive Tract Cancers Susceptibility in Chinese vol.15, pp.11, 2014,
  2. Accuracy of Intraoperative Gross Examination of Myometrial Invasion in Stage I-II Endometrial Cancer vol.15, pp.17, 2014,
  3. Overexpression of Platelet-derived Growth Factor-D as a Poor Prognosticator in Endometrial Cancer vol.15, pp.8, 2014,
  4. The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update vol.89, pp.3, 2015,
  5. CYP1A1 MspI Polymorphism and Cervical Carcinoma Risk in the Multi-Ethnic Population of Malaysia: a Case-Control Study vol.17, pp.1, 2016,
  6. Association of 42 SNPs with genetic risk for cervical cancer: an extensive meta-analysis vol.16, pp.1, 2015,
  7. Risk factors for endometrial cancer: An umbrella review of the literature pp.00207136, 2019,